| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Ethylene-vinyl acetate copolymer does not have a specific biological target as it is a polymeric biomaterial rather than a pharmacologically active compound. Its function in biomedical applications is physical rather than biochemical: it serves as a matrix or membrane for the controlled release of therapeutic agents. EVA acts as a diffusion barrier, releasing encapsulated drugs (such as atenolol, triprolidine, and furosemide) at controlled rates through polymer swelling and drug diffusion mechanisms. The polymer itself is inert and does not interact with specific receptors or enzymes. Its utility lies in its biocompatibility, flexibility, and ability to be fabricated into various forms including films, sheets, and microparticles.
|
|---|---|
| ln Vitro |
In vitro, ethylene-vinyl acetate copolymer exhibits no pharmacological activity as it is a biomaterial rather than a drug. Its in vitro performance is evaluated in drug release studies, where the polymer is fabricated into films or matrices containing a model drug, and the release profile is measured in buffer solutions at physiological pH and temperature. EVA has been shown to be an effective matrix for the controlled delivery of atenolol, triprolidine, and furosemide. In cell culture, EVA films support cell adhesion and proliferation, making them suitable for tissue engineering applications. The material does not elicit cytotoxic responses when tested according to ISO 10993 standards for biocompatibility.
|
| ln Vivo |
In vivo, ethylene-vinyl acetate copolymer is used as an implantable biomaterial for drug delivery and tissue engineering applications. When implanted subcutaneously in animal models, EVA devices exhibit good biocompatibility with minimal inflammatory response. Drug-loaded EVA implants release therapeutic agents at controlled rates over extended periods (weeks to months), as demonstrated in studies with various drug candidates. The polymer itself is biostable and does not degrade significantly in vivo, which is advantageous for long-term drug delivery applications. EVA has been used in contraceptive vaginal rings, implantable drug delivery systems, and wound dressings. No intrinsic therapeutic activity is attributed to the polymer itself.
|
| Enzyme Assay |
In vitro assays for ethylene-vinyl acetate copolymer focus on evaluating its performance as a drug delivery matrix rather than receptor binding. A typical protocol involves preparing EVA films by solvent casting or hot pressing, loading the film with a model drug, and placing the film in a dissolution apparatus containing phosphate-buffered saline (pH 7.4) at 37°C. Samples are withdrawn at predetermined time points and analyzed by HPLC or UV spectroscopy to quantify drug release. Release kinetics are modeled using zero-order, first-order, or Higuchi equations. For biocompatibility testing, EVA samples are extracted in cell culture media and the extracts are tested for cytotoxicity using standard assays such as MTT or LDH release.
|
| Cell Assay |
In vitro cell culture experiments with ethylene-vinyl acetate copolymer evaluate its biocompatibility and suitability as a scaffold for cell growth. A standard protocol involves sterilizing EVA films or discs by UV irradiation or ethanol treatment, then placing them in 24-well or 96-well plates. Cells (e.g., fibroblasts, osteoblasts, or endothelial cells) are seeded onto the polymer surface at densities of 1-5 × 10⁴ cells/cm² and cultured in standard media at 37°C with 5% CO₂ for 3-7 days. Cell adhesion, proliferation, and morphology are assessed by microscopy, while viability is measured using MTT or Live/Dead staining. Cytotoxicity is evaluated by comparing cell growth on EVA to tissue culture polystyrene controls.
|
| Animal Protocol |
In vivo animal experiments with ethylene-vinyl acetate copolymer typically involve implantation studies to evaluate biocompatibility and drug delivery performance. A standard protocol involves implanting EVA devices (films, rods, or microparticles) subcutaneously or intramuscularly in rodents (rats or mice) under sterile surgical conditions. Animals are monitored for signs of infection, inflammation, or rejection over periods ranging from days to months. At study termination, the implantation sites are excised and examined histologically for tissue reaction, capsule formation, and inflammatory cell infiltration. For drug delivery studies, blood samples are collected at regular intervals to measure drug concentrations and assess release kinetics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ethylene-vinyl acetate copolymer itself are not applicable as it is a non-absorbable biomaterial. When used as a drug delivery matrix, the pharmacokinetics of the released drug are determined by the release kinetics from the EVA device and the drug's own absorption, distribution, metabolism, and excretion properties. EVA is biostable and does not degrade in vivo, meaning that the polymer remains at the implantation site and is not systemically absorbed. There is no metabolism or excretion of the polymer itself. The release rate of drugs from EVA matrices is typically zero-order, providing constant drug delivery over extended periods.
|
| Toxicity/Toxicokinetics |
Ethylene-vinyl acetate copolymer is generally considered a non-toxic material with excellent biocompatibility. It has been used in FDA-approved medical devices including contraceptive vaginal rings, drug-eluting stents, and wound dressings. The material does not elicit significant inflammatory responses and is not known to be mutagenic, carcinogenic, or reproductively toxic. EVA is stable and combustible; it is incompatible with strong oxidizing agents and bases. The polymer contains antioxidants (typically 400-1200 ppm BHT) to prevent oxidative degradation. Standard handling precautions for thermoplastic materials apply. EVA is not intended for internal use as a drug substance but is considered safe for use in medical devices.
|
| Additional Infomation |
See also: ...View more...
Ethylene-vinyl acetate copolymer is widely used in the medical and pharmaceutical industries for controlled drug delivery applications. It has been used as a matrix for contraceptive vaginal rings (e.g., NuvaRing), implantable drug delivery systems, transdermal patches, and wound dressings. EVA is also used in orthotics, surfboard traction pads, artificial flowers, plastic wraps, HEPA filters, and thermoplastic mouthguards. The material is permitted for use as an inert ingredient in non-food pesticide products. EVA is not a pharmaceutical active ingredient and has not undergone clinical trials as a drug. Its mechanism of action in drug delivery is physical—diffusion-controlled release of encapsulated therapeutic agents through the polymer matrix. |
| Molecular Formula |
(C2H4)N(C4H6O2)M
|
|---|---|
| Molecular Weight |
114.1424
|
| Exact Mass |
114.068
|
| CAS # |
24937-78-8
|
| Related CAS # |
125229-71-2;109785-00-4;68608-67-3;104912-80-3;24937-78-8;106444-63-7
|
| PubChem CID |
175988
|
| Appearance |
White to off-white liquid（Density：0.948 g/cm3）
|
| Density |
0.948 g/mL at 25ºC
|
| Boiling Point |
170.6ºC at 760mmHg
|
| Melting Point |
99ºC
|
| Flash Point |
260ºC
|
| Vapour Pressure |
0.714mmHg at 25°C
|
| LogP |
1.495
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
65.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=C.C=COC(=O)C
|
| InChi Key |
HDERJYVLTPVNRI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H6O2.C2H4/c1-3-6-4(2)5;1-2/h3H,1H2,2H3;1-2H2
|
| Chemical Name |
ethene;ethenyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.7612 mL | 43.8059 mL | 87.6117 mL | |
| 5 mM | 1.7522 mL | 8.7612 mL | 17.5223 mL | |
| 10 mM | 0.8761 mL | 4.3806 mL | 8.7612 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
